In vitro drug-drug interaction studies: What, when and why?

April 28, 2021
8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST - Duration: 60 Minutes


Because different medications are commonly used simultaneously, interactions between co-administered drugs may have a considerable impact on drug safety and efficacy. Pharmacokinetic drug-drug interactions (DDI), in which one drug affects the absorption, distribution, metabolism or excretion (ADME) of another drug, may result in altered drug exposure and consequently either loss of efficacy or increased risk for adverse effects in patients. Insight into mechanisms causing pharmacokinetic DDIs is required for the evaluation and management of clinical risks caused by these interactions. Currently, in vitro methods to investigate both metabolism- and transporter-based interactions are an integral part of such evaluation.

This webinar will outline mechanisms causing metabolism- and transporter-based interactions and illustrate the impact of interactions for both the ‘victim’ and ‘perpetrator’ of DDI. Furthermore, the routinely used in vitro methods for addressing DDI risks and translation of in vitro results into clinical predictions, and potential timing of such studies during drug discovery and development process are discussed.

Brought to you by:


Aki Heikkinen
Head of Enzyme Inhibitions, Transporters and PBPK at Admescope
Ann Thayer
Contributing Editor,
C&EN Media Group


*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) via email, in accordance with the ACS Privacy Policy.

© 2024 American Chemical Society, 1155 16th St NW, Washington, DC 20036, USA. View our Privacy Policy